SPIRIVA® Respimat® in clinical practice – a case study from a UK GP

Dr Kevin Gruffydd-Jones is the respiratory lead for the Royal College of General Practitioners (RCGP) in the UK and an adviser to the National Institute of Health and Care Excellence (NICE) Asthma Management Guideline group.

Citing an interesting case of a highly atopic patient he did not expect to benefit from SPIRIVA® Respimat®, Dr Gruffydd-Jones describes the treatments he prescribed before turning to SPIRIVA® Respimat®.

Spiriva-Asthma-External-Video_2017_Interview with KEVIN GRUFFYDD-JONES_4_0.1

House dust and cats were the triggers for rhinitis and eczema in a 48 years old male patient who had had a bad asthma exacerbation after moving into a dusty house. This was treated by oral steroids. The patient was already using combination therapy. Having initially increased his patient’s dose of inhaled corticosteroids (ICS), and subsequently prescribed montelukast without any benefit, Dr Gruffydd-Jones decided to try SPIRIVA® Respimat®, although he hadn’t thought of it as a drug for people with allergic asthma. After using SPIRIVA® Respimat® his patient’s use of salbutamol was reduced.